The Role of Home Packs of HIV PEPSE in High Risk Individuals
Status:
Completed
Trial end date:
2021-03-16
Target enrollment:
Participant gender:
Summary
The study is looking at a new way to reduce the risk of catching HIV. Post-exposure
Prophylaxis for sexual exposure (PEPSE) is where a month of HIV drugs can be given to reduce
the chance of getting HIV, after a risk. To improve its use the Investigators want to see
whether providing a 5-day course of PEPSE for people to keep at home (HOME PEPSE) will lead
to it being taken much quicker than having to get it from sexual health clinics or A&E. The
HOME PEPSE packs contain HIV tablets that are used in routine HIV care. However the type of
HIV drugs are slightly different to those currently used in PEPSE and the Investigators hope
that they will have fewer side effects. HOME PEP consists of Truvada and Maraviroc.
140 gay men who are at high risk of getting HIV will be randomised to one of two groups.
Group A will receive HOME PEPSE immediately and group B will receive HOME PEPSE after 48
weeks on the study.
Phase:
Phase 4
Details
Lead Sponsor:
Guy's and St Thomas' NHS Foundation Trust
Collaborators:
Gilead Sciences ViiV Healthcare
Treatments:
Emtricitabine Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Maraviroc Tenofovir